Compare SQNS & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SQNS | CTMX |
|---|---|---|
| Founded | 2003 | 2008 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.4M | 642.2M |
| IPO Year | 2011 | 2015 |
| Metric | SQNS | CTMX |
|---|---|---|
| Price | $3.24 | $3.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $20.33 | $12.10 |
| AVG Volume (30 Days) | 116.3K | ★ 5.1M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $76,201,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $49.79 | $7.61 |
| P/E Ratio | ★ N/A | $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.73 | $1.72 |
| 52 Week High | $10.93 | $8.21 |
| Indicator | SQNS | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 46.72 | 59.51 |
| Support Level | $2.86 | $3.40 |
| Resistance Level | $4.60 | $3.90 |
| Average True Range (ATR) | 0.24 | 0.21 |
| MACD | 0.02 | 0.12 |
| Stochastic Oscillator | 56.73 | 76.10 |
Sequans Communications SA is a fabless semiconductor company specializing in wireless 4G and 5G cellular technologies for the Internet of Things (IoT). Sequans' engineers design and develop, secure, and energy-efficient semiconductor solutions that enable the next generation of AI-connected applications, including smart energy metering, industrial automation, smart mobility and logistics, secure payments, e-health, and smart home solutions. The Company offers a comprehensive portfolio of wireless connectivity solutions, including radio frequency (RF) transceivers, integrated circuits (ICs) for baseband processing, as well as modules, software, & protocol stacks. The Company has one operating segment, which is the design & marketing of semiconductor components for cellular wireless systems.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.